Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Teva Pharmaceutical Industries ADR (NY: TEVA )

18.45 +0.01 (+0.05%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries ADR

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report
Despite significant initiatives by generic drug companies to broaden access to vital medicines, many vulnerable patients remain underserved, according to findings from a new study from the Access to... 
Via Benzinga
3 No-Brainer Stocks to Buy With $20 Right Now
You don't need a boatload of cash to begin growing your wealth on Wall Street. 
Via The Motley Fool
Why Can't You Find Adderall? Inside the Ongoing Shortage of ADHD Medication In US
Last year, Teva Pharmaceutical Industries Ltd (NYSE: TEVA), the primary producer of Adderall, faced shortages  
Via Benzinga
TEVA - A Pharma Stock To Watch
TEVA is one of the few instruments that has handily cleared its July 6-month calendar range high. The 50 daily moving average is about to cross or golden cross the 200-DMA and enter a bullish phase. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Teva Takes A Run At Its 200-Day Line After Second-Quarter Beat And Raise
The company also raised the lower boundary of its guidance for full-year sales. 
Via Investor's Business Daily
How A Small Indian Firm Firm Was Pulled Into A Legal Battle with Big Pharma Over A Cancer Drug
This story was first published on the Benzinga India portal. 
Via Benzinga
Bristol Myers' Antitrust Allegations: Lawsuit Over Alleged Patent Deception For Blood Cancer Drug
Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
S&P Slashes Ratings Of Five US Banks, SEC Fines Fintech Adviser Titan For Misleading Crypto Claims, Microsoft Modifies Activision Blizzard Purchase: Today's Top Stories
Benzinga 
Via Benzinga
Topics Regulatory Compliance Stocks
Exposures Legal Regulatory US Equities
Big Pharma Price-Fixing: Teva and Glenmark's $255M Settlement Shines Light on Industry Issues
Drugmaker Teva Pharmaceutical Industries Limited (NYSE: TEVA) has  
Via Benzinga
Teva Settles Price Fixing Charges With U.S. DOJ
From Teva Pharmaceutical Industries Limited
Via Business Wire
FDA Greenlights Expanded Use Of Neurocrine Biosciences' Ingrezza: Analysts Weigh In Depression Warning
The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated  
Via Benzinga
Exposures Product Safety
Supreme Court Halts Purdue Pharma's $6B Settlement: Sackler Family's Shield From Opioid Lawsuits Challenged
On Thursday, the Supreme Court temporarily blocked a $6-billion bankruptcy settlement by Purdue Pharma, the maker of the opioid OxyContin, that would shield the Sackler family from civil lawsuits... 
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Teva Pharmaceutical, Marathon Oil And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by over 1% on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Teva Pharmaceutical Industries (TEVA) Q2 2023 Earnings Call Transcript
TEVA earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Humana, Waters, e.l.f. Beauty, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Wednesday. Here are some big stocks recording gains in today’s session. Powell Industries, Inc. (NASDAQ: POWL) shares jumped... 
Via Benzinga
Why Exact Sciences Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers WaveDancer, Inc. (NASDAQ: WAVD) shares climbed 86% to $0.5505. Tellenger, a subsidiary of Wavedancer, Inc., won a seven-year U.S. government contract. 
Via Benzinga
Teva Pharma's Stock Soars On Q2 Profit Beat, Highlights Strong Growth From Austedo
Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Q2 sales reached $3.88 billion, up 2% Y/Y (4% on constant currency), slightly beating the  
Via Benzinga
Teva Reports Second Quarter 2023 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
From Teva Pharmaceutical Industries Limited
Via Business Wire
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen 
Via Benzinga
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Alvotech
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
Via Benzinga
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva's Strategic Evaluation: Israeli Pharma Company Mulls Divesting $2B Active Ingredients Unit
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is reportedly considering potential strategic options for its active pharmaceutical ingredients (API) unit, which could include a potential sale.  
Via Benzinga
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.